View, browse and sort the list of CPhI North America Conference sessions and show floor programming by pass type, track, and format. Seating is first come, first serve, so please arrive early to sessions that you would like to attend. Sessions are subject to change.

Excipient Innovation and Its Impact on Drug Development Part II


Thiago Carvalho Ph.D. (Senior Research Investigator in Drug Product Science & Technology , Bristol‐Myers Squibb)

Nigel Langley (Director Technical Service and Scientific Affairs, BASF Pharma Solutions)

David Schoneker (Director of Global Regulatory Affairs, Colorcon, Inc)

Joe Zeleznik (Manager of Technical Affairs, MEGGLE USA)

Location: 119B

Date: Wednesday, April 25

Time: 10:15am - 11:00am

Pass Type: Conference Pass, VIP Attendee - Get your pass now!

Track: Drug Manufacturing

Vault Recording: TBD

This session will be presented in a Fireside Chat type format intended to garner audience interaction on several key points related to the need and use of novel excipients.

Panelists from IPEC-Americas and the IQ Consortium will further discuss the issues identified in Part 1 of this topic and ask the audience several key questions concerning what they think the critical driving needs are for novel excipients, what the hurdles are in their companies that may prevent the use of various types of novel excipients and what they think might be ways to facilitate innovation and the use of novel excipients to resolve formulation and production problems or enhance quality and productivity within the industry.

Session takeaways:

  • Develop an understanding of why there is a pressing need for various types of novel excipients to solve difficult drug development problems, facilitate new manufacturing methods, lower costs and what regulatory hurdles appear to exist

  • Identify how each participant can contribute to further development and use of novel excipients at their companies and throughout the pharmaceutical industry

  • Become confident in using novel excipients to resolve unique formulation and manufacturing problems rather than simply utilize existing excipients that may not create the best drug possible from a quality and performance perspective

Presentation File